PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Funding Update

23 Feb 2012 16:36

RNS Number : 0271Y
Amphion Innovations PLC
23 February 2012
 



 

Amphion Innovations plcNew Debt Facility

London and New York, 23 February 2012- Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces it has secured additional unsecured loan financing of $500,000 from R. James Macaleer, Chairman of Amphion, who is also interested in 17.37% of the issued share capital of the Company. The loan is repayable on 21 August 2012 and carries interest at 7 per cent per annum.

Mr. Macaleer will also receive 500,000 warrants. Each warrant will entitle the holder to subscribe for one Ordinary Share at 8 pence per Ordinary Share and will have an expiration date of 31 December 2013.

This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company's nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

For further information please contact:

Amphion Innovations

Charlie Morgan

+1 212 210 6224

 

Cardew Group

Tim Robertson

+44 (0)20 7930 0777

 

Seymour Pierce Limited, Nominated Advisor

Freddy Crossley/ Mark Percy

+44 (0)20 7107 8000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEEFMDFESEDE
Date   Source Headline
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.